Cargando…

Serum-Dependence of Affinity-Mediated VEGF Release from Biomimetic Microspheres

[Image: see text] Vascular endothelial growth factor (VEGF) activity is highly regulated via sequestering within the ECM and cell-demanded proteolysis to release the sequestered VEGF. Numerous studies have demonstrated that VEGF activity mediates cellular events leading to angiogenesis and capillary...

Descripción completa

Detalles Bibliográficos
Autores principales: Belair, David G., Khalil, Andrew S., Miller, Michael J., Murphy, William L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059260/
https://www.ncbi.nlm.nih.gov/pubmed/24773176
http://dx.doi.org/10.1021/bm500177c
_version_ 1782321222165463040
author Belair, David G.
Khalil, Andrew S.
Miller, Michael J.
Murphy, William L.
author_facet Belair, David G.
Khalil, Andrew S.
Miller, Michael J.
Murphy, William L.
author_sort Belair, David G.
collection PubMed
description [Image: see text] Vascular endothelial growth factor (VEGF) activity is highly regulated via sequestering within the ECM and cell-demanded proteolysis to release the sequestered VEGF. Numerous studies have demonstrated that VEGF activity mediates cellular events leading to angiogenesis and capillary formation in vivo. This has motivated the study of biomaterials to sustain VEGF release, and in many cases, the materials are inspired by the structure and function of the native ECM. However, there remains a need for materials that can bind to VEGF with high specificity, as the in vivo environment is rich in a variety of growth factors (GFs) and GF-binding moieties. Here we describe a strategy to control VEGF release using hydrogel microspheres with tethered peptides derived from VEGF receptor 2 (VEGFR2). Using biomaterials covalently modified with varying concentrations of two distinct VEGFR2-derived peptides with varying serum stability, we analyzed both biomaterial and environmental variables that influence VEGF release and activity. The presence of tethered VEGF-binding peptides (VBPs) resulted in significantly extended VEGF release relative to control conditions, and the resulting released VEGF significantly increased the expansion of human umbilical vein endothelial cells in culture. VEGF release rates were also strongly influenced by the concentration of serum. The presence of Feline McDonough Sarcoma-like tyrosine kinase 1 (sFlt-1), a serum-borne receptor fragment derived from VEGF receptor 1, increased VEGF release rates, although sFlt-1 was not sufficient to recapitulate the release profile of VEGF in serum. Further, the influence of serum on VEGF release was not due to protease activity or nonspecific VEGF interactions in the presence of serum-borne heparin. VEGF release kinetics correlated well with a generalizable mathematical model describing affinity-mediated release of VEGF from hydrogel microspheres in defined conditions. Modeling results suggest a potential mechanism whereby competition between VEGF and multiple VEGF-binding serum proteins including sFlt-1, soluble kinase insert domain receptor (sKDR), and α2-macroglobulin (α2-M) likely influenced VEGF release from microspheres. The materials and mathematical model described in this approach may be useful in a range of applications in which sustained, biologically active GF release of a specific GF is desirable.
format Online
Article
Text
id pubmed-4059260
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-40592602015-04-29 Serum-Dependence of Affinity-Mediated VEGF Release from Biomimetic Microspheres Belair, David G. Khalil, Andrew S. Miller, Michael J. Murphy, William L. Biomacromolecules [Image: see text] Vascular endothelial growth factor (VEGF) activity is highly regulated via sequestering within the ECM and cell-demanded proteolysis to release the sequestered VEGF. Numerous studies have demonstrated that VEGF activity mediates cellular events leading to angiogenesis and capillary formation in vivo. This has motivated the study of biomaterials to sustain VEGF release, and in many cases, the materials are inspired by the structure and function of the native ECM. However, there remains a need for materials that can bind to VEGF with high specificity, as the in vivo environment is rich in a variety of growth factors (GFs) and GF-binding moieties. Here we describe a strategy to control VEGF release using hydrogel microspheres with tethered peptides derived from VEGF receptor 2 (VEGFR2). Using biomaterials covalently modified with varying concentrations of two distinct VEGFR2-derived peptides with varying serum stability, we analyzed both biomaterial and environmental variables that influence VEGF release and activity. The presence of tethered VEGF-binding peptides (VBPs) resulted in significantly extended VEGF release relative to control conditions, and the resulting released VEGF significantly increased the expansion of human umbilical vein endothelial cells in culture. VEGF release rates were also strongly influenced by the concentration of serum. The presence of Feline McDonough Sarcoma-like tyrosine kinase 1 (sFlt-1), a serum-borne receptor fragment derived from VEGF receptor 1, increased VEGF release rates, although sFlt-1 was not sufficient to recapitulate the release profile of VEGF in serum. Further, the influence of serum on VEGF release was not due to protease activity or nonspecific VEGF interactions in the presence of serum-borne heparin. VEGF release kinetics correlated well with a generalizable mathematical model describing affinity-mediated release of VEGF from hydrogel microspheres in defined conditions. Modeling results suggest a potential mechanism whereby competition between VEGF and multiple VEGF-binding serum proteins including sFlt-1, soluble kinase insert domain receptor (sKDR), and α2-macroglobulin (α2-M) likely influenced VEGF release from microspheres. The materials and mathematical model described in this approach may be useful in a range of applications in which sustained, biologically active GF release of a specific GF is desirable. American Chemical Society 2014-04-29 2014-06-09 /pmc/articles/PMC4059260/ /pubmed/24773176 http://dx.doi.org/10.1021/bm500177c Text en Copyright © 2014 American Chemical Society
spellingShingle Belair, David G.
Khalil, Andrew S.
Miller, Michael J.
Murphy, William L.
Serum-Dependence of Affinity-Mediated VEGF Release from Biomimetic Microspheres
title Serum-Dependence of Affinity-Mediated VEGF Release from Biomimetic Microspheres
title_full Serum-Dependence of Affinity-Mediated VEGF Release from Biomimetic Microspheres
title_fullStr Serum-Dependence of Affinity-Mediated VEGF Release from Biomimetic Microspheres
title_full_unstemmed Serum-Dependence of Affinity-Mediated VEGF Release from Biomimetic Microspheres
title_short Serum-Dependence of Affinity-Mediated VEGF Release from Biomimetic Microspheres
title_sort serum-dependence of affinity-mediated vegf release from biomimetic microspheres
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059260/
https://www.ncbi.nlm.nih.gov/pubmed/24773176
http://dx.doi.org/10.1021/bm500177c
work_keys_str_mv AT belairdavidg serumdependenceofaffinitymediatedvegfreleasefrombiomimeticmicrospheres
AT khalilandrews serumdependenceofaffinitymediatedvegfreleasefrombiomimeticmicrospheres
AT millermichaelj serumdependenceofaffinitymediatedvegfreleasefrombiomimeticmicrospheres
AT murphywilliaml serumdependenceofaffinitymediatedvegfreleasefrombiomimeticmicrospheres